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Acceptability study on Nutricomp® Drink Plus in adult patients: Evaluation of 
gastrointestinal (GI) tolerance, palatability and compliance  
by N. Trott, M. Kurien and D. S. Sanders, Academic Unit of Gastroenterology, Royal 
Hallamshire Hospital, Sheffield, United Kingdom 
 
Malnutrition is common in hospitalised patients. It can influence morbidity and 
mortality, as well as recovery time and hospital length of stay. For patients with functioning 
gastrointestinal tracts who are unable to meet their energy and nutrient requirements with 
normal food intake, nutritional support is recommended using oral nutritional supplements 
(ONS). This study assesses the GI tolerance, palatability and compliance of a new ONS 
(Nutricomp® Drink Plus, B Braun Melsungen AG).  The ONS drinks were initially 
prescribed in hospital with patients taking the supplements on 7 consecutive days either in a 
hospital or in the community setting.  
This prospective open label study was conducted in a University Teaching Hospital. 
The recruitment target was 15 patients with inclusion criteria comprising patients who are 
adults (18 years+) with a MUST score    1 and an anticipated period of nutritional support  
7 days. Each patient tasted all 4 flavours (vanilla, strawberry, chocolate, banana) of 
Nutricomp® Drink Plus, completing a palatability questionnaire for each. The patients took 
the Investigational Product (IP) for a period of 7 days. A patient diary that documented IP 
daily intake, GI tolerance parameters and compliance was completed for each patient for this 
7 day period. 
Of the 23 patients that provided informed consent most were hospitalised due to 
oncological treatment (56.5%, of which approximately half had underlying malignant disease 
of the gastrointestinal tract, liver or spleen) or maxillary osteostomy (21.7%). 15 patients 
successfully completed the study by taking the prescribed IP for 7 consecutive days. 8 
patients did not complete the study according to the protocol. Nutricomp® Drink Plus 
showed mostly 'good' to 'very good', but at least 'acceptable' results concerning the several 
acceptability parameters evaluated including colour, smell, texture, taste and overall 
acceptance of the product. 26 gastrointestinal adverse events were documented in 10 of 23 
patients, none of which were considered to be serious,  judged as being related to the IP or led 
to discontinuation of the IP. The calculated overall compliance was 93.8% (SD 30.7) and  
Nutricomp® Drink Plus  was judged as acceptable by 94.4% of all patients. For the 15 
patients that competed the study, calculated compliance was 100% (SD 27.6%) for the total 
treatment period. All of these 15 patients also confirmed that they would continue using 
Nutricomp® Drink Plus if necessary and would recommend Nutricomp® Drink Plus to other 
people in need of an ONS.  
This is the first UK study to evaluate Nutricomp® Drink Plus, demonstrating good 
tolerability, acceptability, safety profile and compliance. No adverse events relating to 
Nutricomp Drink plus were reported during the study. Nutricomp® Drink Plus was shown to 
be acceptable, palatable and well tolerated in patients with a generally reduced health status 
or a vulnerable/ pre-damaged GI system.  
